Daphne Karydas's most recent trade in Compass Pathways Plc - ADR was a trade of 26,000 Share Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Compass Pathways Plc - ADR | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 26,000 | 26,000 | - | - | Share Option (Right to Buy) | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 32,900 | 32,900 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 22,000 | 22,000 | - | - | Stock Option | |
| Compass Pathways Plc - ADR | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 26,000 | 26,000 | - | - | Share Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Daphne Karydas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) |